Last reviewed · How we verify

MVA-BN-Filo 5*10^7 Inf. U.

Janssen Vaccines & Prevention B.V. · Phase 3 active Biologic

MVA-BN-Filo 5*10^7 Inf. U. is a Viral vector vaccine Biologic drug developed by Janssen Vaccines & Prevention B.V.. It is currently in Phase 3 development for Prevention of Ebola virus disease, Prevention of Marburg virus disease.

MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.

MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses. Used for Prevention of Ebola virus disease, Prevention of Marburg virus disease.

At a glance

Generic nameMVA-BN-Filo 5*10^7 Inf. U.
SponsorJanssen Vaccines & Prevention B.V.
Drug classViral vector vaccine
TargetFilovirus glycoproteins (Ebola virus GP, Marburg virus GP)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

This vaccine uses a non-replicating MVA vector to deliver Filovirus surface antigens, stimulating both cellular and humoral immune responses. It is designed as a prime component in heterologous prime-boost vaccination regimens against Ebola virus disease and Marburg virus disease, working to establish protective immunity before potential exposure to these pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MVA-BN-Filo 5*10^7 Inf. U.

What is MVA-BN-Filo 5*10^7 Inf. U.?

MVA-BN-Filo 5*10^7 Inf. U. is a Viral vector vaccine drug developed by Janssen Vaccines & Prevention B.V., indicated for Prevention of Ebola virus disease, Prevention of Marburg virus disease.

How does MVA-BN-Filo 5*10^7 Inf. U. work?

MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.

What is MVA-BN-Filo 5*10^7 Inf. U. used for?

MVA-BN-Filo 5*10^7 Inf. U. is indicated for Prevention of Ebola virus disease, Prevention of Marburg virus disease.

Who makes MVA-BN-Filo 5*10^7 Inf. U.?

MVA-BN-Filo 5*10^7 Inf. U. is developed by Janssen Vaccines & Prevention B.V. (see full Janssen Vaccines & Prevention B.V. pipeline at /company/janssen-vaccines-prevention-b-v).

What drug class is MVA-BN-Filo 5*10^7 Inf. U. in?

MVA-BN-Filo 5*10^7 Inf. U. belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is MVA-BN-Filo 5*10^7 Inf. U. in?

MVA-BN-Filo 5*10^7 Inf. U. is in Phase 3.

What are the side effects of MVA-BN-Filo 5*10^7 Inf. U.?

Common side effects of MVA-BN-Filo 5*10^7 Inf. U. include Injection site pain/erythema, Myalgia, Fatigue, Headache, Fever.

What does MVA-BN-Filo 5*10^7 Inf. U. target?

MVA-BN-Filo 5*10^7 Inf. U. targets Filovirus glycoproteins (Ebola virus GP, Marburg virus GP) and is a Viral vector vaccine.

Related